SOTYKTU Drug Patent Profile

When do Sotyktu patents expire, and what generic alternatives are available?

Sotyktu is a drug marketed by Bristol and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and fifteen patent family members in forty countries.

The generic ingredient in SOTYKTU is deucravacitinib. One supplier is listed for this compound. Additional details are available on the deucravacitinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Sotyktu

Sotyktu will be eligible for patent challenges on September 9, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 7, 2033. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SOTYKTU

International Patents:	115
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	31
Clinical Trials:	4
Patent Applications:	241
Drug Prices:	Drug price information for SOTYKTU
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SOTYKTU
What excipients (inactive ingredients) are in SOTYKTU?	SOTYKTU excipients list
DailyMed Link:	SOTYKTU at DailyMed

See drug prices for SOTYKTU

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SOTYKTU

NDA:

214958

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SOTYKTU

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Beth Israel Deaconess Medical Center	Phase 2
Bristol-Myers Squibb	Phase 2
Bristol-Myers Squibb	Phase 4

See all SOTYKTU clinical trials

Pharmacology for SOTYKTU

Drug Class	Tyrosine Kinase 2 Inhibitor
Mechanism of Action	Tyrosine Kinase 2 Inhibitors

US Patents and Regulatory Information for SOTYKTU

SOTYKTU is protected by six US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958-001	Sep 9, 2022		RX	Yes	Yes			Y
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958-001	Sep 9, 2022		RX	Yes	Yes
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958-001	Sep 9, 2022		RX	Yes	Yes

EU/EMA Drug Approvals for SOTYKTU

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bristol-Myers Squibb Pharma EEIG	Sotyktu	deucravacitinib	EMEA/H/C/005755Treatment of moderate-to-severe plaque psoriasis in adults.	Authorised	no	no	no	2023-03-24

International Patents for SOTYKTU

When does loss-of-exclusivity occur for SOTYKTU?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

France

Hong Kong

Hungary

Japan

Lithuania

Luxembourg

Malaysia

Mexico

Morocco

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Turkey

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SOTYKTU around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	094452
Australia	2013341186
Australia	2017201076

Supplementary Protection Certificates for SOTYKTU

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2922846	301238	Netherlands		PRODUCT NAME: DEUCRAVACITINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/23/1718 20230327
2922846	CA 2023 00024	Denmark		PRODUCT NAME: DEUCRAVACITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/23/1718 20230327
2922846	PA2023523	Lithuania		PRODUCT NAME: DEUKRAVACITINIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1718 20230324

Sotyktu Market Dynamics and Financial Trajectory: Deucravacitinib Sales, Competition, Patents, and Generic Risk

Last updated: August 2, 2026

Sotyktu, Bristol Myers Squibb’s deucravacitinib, is the first approved selective TYK2 inhibitor and the company’s main small-molecule growth product in immunology. Its commercial opportunity rests on expansion beyond plaque psoriasis into psoriatic arthritis, inflammatory bowel disease, lupus, and other immune-mediated conditions. Sales growth has been strong from a low base, but the product competes against entrenched IL-17 and IL-23 biologics, established oral therapies, and emerging TYK2 drugs.

Bristol Myers Squibb reported Sotyktu sales of approximately $277 million in 2023, compared with about $25 million in 2022. The product was still in launch-phase commercialization, with market access, international rollout, and physician adoption determining its financial trajectory. [1]

What is Sotyktu and how does deucravacitinib work?

Sotyktu is an oral, once-daily tablet containing deucravacitinib. It selectively inhibits TYK2 through the regulatory pseudokinase domain rather than blocking the ATP-binding catalytic site used by many conventional kinase inhibitors.

The mechanism reduces signaling mediated by interleukin-12, interleukin-23, and type I interferons. This differentiates Sotyktu from:

• JAK1, JAK2, and JAK3 inhibitors, which have broader kinase activity.
• IL-17 biologics, including secukinumab and ixekizumab.
• IL-23 biologics, including guselkumab, risankizumab, and tildrakizumab.
• PDE-4 inhibitors such as apremilast.

The commercial argument for Sotyktu is an oral, targeted immunomodulator with durable efficacy and a safety profile positioned between broad oral kinase inhibition and injectable biologic treatment.

What is the FDA status of Sotyktu?

The FDA approved Sotyktu on September 9, 2022, for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. [2]

FDA-approved indication

Item	Status
Active ingredient	Deucravacitinib
Brand	Sotyktu
Sponsor	Bristol Myers Squibb
Dosage form	Oral tablet
Dose	6 mg once daily
Initial approval	September 9, 2022
FDA indication	Moderate-to-severe plaque psoriasis in adults
Regulatory pathway	New molecular entity, small molecule
Biosimilar pathway	Not applicable

Sotyktu’s label includes warnings relating to infections, tuberculosis evaluation, malignancy, laboratory abnormalities, liver effects, and immunizations. Unlike several JAK inhibitors, deucravacitinib is designed to avoid direct inhibition of JAK catalytic domains. That distinction supports the product’s safety positioning, although physicians continue to evaluate infection and malignancy risks associated with systemic immunosuppression.

Bristol Myers Squibb has pursued additional indications in psoriatic arthritis, systemic lupus erythematosus, inflammatory bowel disease, and other immune-mediated diseases. Regulatory expansion is central to the product’s long-term value because psoriasis alone has a crowded treatment market and substantial biologic competition.

How much revenue does Sotyktu generate?

Sotyktu revenue increased sharply during its initial launch period.

Fiscal year	Reported Sotyktu sales	Commercial status
2022	Approximately $25 million	Initial launch period
2023	Approximately $277 million	Broad U.S. launch and international expansion
2024	Subject to Bristol Myers Squibb annual reporting	Expansion and indication-development phase

Bristol Myers Squibb’s 2023 sales increase reflected greater physician adoption, formulary access, and increased use among patients seeking an oral alternative to injectable biologics. [1] The product remained a relatively small contributor to Bristol Myers Squibb’s total revenue, which exceeded $45 billion in 2023.

Sotyktu’s financial profile is therefore asymmetric:

1. Early revenue growth can be high because the base is small.
2. Absolute sales remain modest relative to the company’s mature products.
3. Value depends on label expansion and sustained use rather than first-line psoriasis share alone.
4. Development costs and commercial investment precede the full return from future indications.

A successful expansion into psoriatic arthritis or lupus would materially increase the addressable population. Failure to establish efficacy in additional diseases would leave Sotyktu concentrated in a competitive psoriasis market.

What drives Sotyktu market growth?

Sotyktu growth is driven by five commercial factors.

Oral administration

Many psoriasis patients prefer oral therapy over injections. Sotyktu can compete for patients who are unwilling to start or continue biologic treatment, particularly those seeking a convenient daily regimen.

Targeted TYK2 mechanism

The TYK2 mechanism gives Bristol Myers Squibb a differentiated scientific and commercial position. The company has promoted deucravacitinib as a selective inhibitor that does not broadly inhibit JAK1, JAK2, or JAK3.

Efficacy in plaque psoriasis

In the POETYK PSO-1 and POETYK PSO-2 trials, Sotyktu demonstrated superior PASI 75 response and static Physician’s Global Assessment responses compared with placebo and apremilast. [3] Long-term data showed maintenance of clinical response in a substantial proportion of treated patients.

Biologic sequencing

Sotyktu can be used after inadequate response to topical treatment, phototherapy, or systemic therapy. Its commercial role may expand as a treatment before biologic initiation or after failure of an injectable product.

Indication expansion

The most important potential value driver is development outside plaque psoriasis. Psoriatic arthritis is a logical adjacent market because the disease overlaps with psoriasis, although efficacy and label differentiation must be established against established biologic standards.

How does Sotyktu compare with competing TYK2 drugs?

Sotyktu competes with both current therapies and pipeline TYK2 inhibitors.

Product	Company	Mechanism	Route	Key commercial distinction
Sotyktu	Bristol Myers Squibb	Selective TYK2 pseudokinase inhibitor	Oral	First approved TYK2 inhibitor
BMS-986322	Bristol Myers Squibb	TYK2 inhibitor	Oral	Pipeline follow-on asset
VTX958	Ventyx Biosciences	Selective TYK2 inhibitor	Oral	Pipeline, gastrointestinal and immune indications
ICP-332 / other TYK2 programs	Multiple companies	TYK2 inhibition	Oral or topical	Development-stage competition
Otezla	Amgen	PDE-4 inhibitor	Oral	Established oral psoriasis therapy
Rinvoq	AbbVie	JAK1 inhibitor	Oral	Broad immunology label and strong commercial presence
Bimzelx	UCB	IL-17A/F biologic	Injection	High-efficacy biologic competitor
Tremfya	Johnson & Johnson	IL-23 biologic	Injection	Established psoriasis and psoriatic arthritis presence
Skyrizi	AbbVie	IL-23 biologic	Injection	Large immunology franchise
Taltz	Eli Lilly	IL-17A biologic	Injection	Established psoriasis and psoriatic arthritis product

Sotyktu’s most direct competitive advantage is oral delivery combined with selective TYK2 pharmacology. Its principal weakness is that biologics often deliver higher skin-clearance rates in head-to-head clinical practice and have strong specialist familiarity.

What patents protect Sotyktu?

Sotyktu is protected by compound, formulation, treatment-method, and regulatory exclusivity rights. The central U.S. compound patent commonly associated with deucravacitinib is U.S. Patent No. 10,519,175, assigned to Bristol-Myers Squibb. Public patent records identify expiration in the late 2030s, subject to patent-term adjustment, patent-term extension, and claim-specific analysis. [4]

Core Sotyktu intellectual-property categories

Protection category	Commercial purpose
Active compound patents	Protect deucravacitinib and related chemical matter
Salt and solid-state patents	Protect pharmaceutical forms and stability
Formulation patents	Protect tablet composition and manufacturing characteristics
Method-of-use patents	Cover treatment of psoriasis and other immune diseases
Manufacturing patents	Protect synthetic routes, intermediates, and process conditions
Regulatory exclusivity	Delays certain competing FDA approvals independently of patent rights

The Orange Book status must be reviewed by product and patent listing because the commercial launch date for an ANDA depends on the listed patents, certifications, litigation, and any settlement terms. The FDA Orange Book identifies patents submitted by the NDA holder and does not itself determine whether a patent is valid or infringed. [5]

When does Sotyktu lose exclusivity?

Sotyktu does not have a single exclusivity date. Market entry depends on the interaction between FDA regulatory exclusivity and patent protection.

Regulatory exclusivity

As a new chemical entity, Sotyktu received five years of FDA data exclusivity. Because the drug was approved in September 2022, the five-year period generally runs into September 2027, subject to the operation of the Hatch-Waxman framework. [6]

The product may also qualify for three-year exclusivity for a supplemental application containing new clinical investigations essential to approval. That period would apply to a specific approved change rather than necessarily blocking all generic versions of the original product.

Patent exclusivity

The principal patent estate is expected to extend materially beyond the basic five-year regulatory period. A generic applicant could challenge listed patents through a Paragraph IV certification before patent expiry. Bristol Myers Squibb could then file infringement litigation, triggering the statutory 30-month stay in the applicable circumstances. [7]

A practical generic-entry window could therefore range from the late 2020s for an aggressive patent challenge to the mid- or late-2030s if core compound claims remain enforceable and no settlement permits an earlier launch.

Are there Paragraph IV challenges to Sotyktu?

No major publicly reported Sotyktu Paragraph IV litigation had established a market-moving generic-entry event through the available public record for the early commercialization period.

The absence of a reported challenge does not remove future risk. Generic applicants may file confidentially until a certification is disclosed through FDA-related processes or litigation. The relevant risk variables are:

• Which patents Bristol Myers Squibb lists in the Orange Book.
• Whether an ANDA applicant challenges compound, formulation, or method claims.
• Whether Bristol Myers Squibb sues within the statutory period.
• Whether the parties settle before trial.
• Whether a court invalidates or narrows the asserted claims.
• Whether a generic applicant receives pediatric or other regulatory advantages.

Because Sotyktu is a small molecule, the competitive pathway is an ANDA, not a biosimilar application.

Does Sotyktu face biosimilar competition?

Sotyktu does not face biosimilar competition in the technical regulatory sense. Deucravacitinib is a chemically synthesized small molecule, so the relevant future competitors are generic tablets approved under the ANDA pathway.

The market can still experience biologic substitution. Patients and payers may shift between Sotyktu and biologic therapies such as IL-17 and IL-23 inhibitors based on:

• Net price and rebates.
• Step-therapy rules.
• Injection preferences.
• Speed and durability of response.
• Safety monitoring.
• Coverage under commercial and government formularies.

What patent litigation and settlement risks affect Sotyktu?

The principal legal risk is future ANDA litigation rather than biosimilar litigation. A generic challenge could target:

• The chemical compound.
• Deucravacitinib salts or polymorphs.
• Tablet formulation.
• Manufacturing processes.
• Treatment methods.

Method-of-use patents are less effective against unrestricted substitution when a generic applicant can pursue a label that omits the patented indication. Compound and formulation patents generally provide stronger commercial protection because they are harder to design around without changing the product itself.

No major publicly disclosed Sotyktu patent settlement was identified in the early launch period. If litigation emerges, a settlement could establish an authorized generic arrangement, a licensed entry date, or restrictions tied to particular indications.

What is Sotyktu’s competitive market outlook?

Sotyktu has a credible position in oral psoriasis therapy but faces a high competitive burden.

Positive market factors

• First-mover status in selective TYK2 inhibition.
• Once-daily oral dosing.
• Strong efficacy in plaque psoriasis trials.
• Potential use before or after biologic therapy.
• Large psoriasis and psoriatic arthritis populations.
• Opportunity for expansion into lupus and gastrointestinal diseases.

Negative market factors

• Large and experienced IL-17 and IL-23 competitors.
• High payer pressure in psoriasis.
• Established oral alternatives, including Otezla and JAK inhibitors.
• Need for long-term safety evidence.
• Dependence on successful clinical development outside psoriasis.
• Potential generic entry after patent challenges.

Sotyktu’s commercial ceiling is likely to be determined by whether Bristol Myers Squibb can establish it as a preferred oral immunology platform rather than a single-indication psoriasis product.

How does Sotyktu compare financially with Bristol Myers Squibb’s major products?

Sotyktu is a growth asset but remains small compared with Bristol Myers Squibb’s leading products.

Product	Therapeutic area	Financial role
Eliquis	Anticoagulation	Large mature franchise with major loss-of-exclusivity exposure
Opdivo	Oncology	Core growth and innovation franchise
Yervoy	Oncology	Established combination oncology product
Reblozyl	Hematology	Growth product acquired through Celgene
Camzyos	Cardiovascular	Emerging specialty product
Sotyktu	Immunology	Early-stage growth product with expansion potential

Sotyktu cannot offset the near-term revenue impact of major mature-product patent expirations on its own. Its strategic value is as part of Bristol Myers Squibb’s replacement pipeline, alongside newer products such as Camzyos and Reblozyl.

What generic launch scenarios exist for Sotyktu?

Scenario 1: No early Paragraph IV challenge

Generic entry follows the enforceable expiry of core patents. Sotyktu retains branded pricing and market access, subject to therapeutic competition.

Scenario 2: Paragraph IV settlement

Bristol Myers Squibb settles with one or more generic applicants and permits entry before the latest patent expiry. The launch date could be accompanied by an authorized generic or limited license.

Scenario 3: Patent invalidation

A court invalidates or narrows a core compound or formulation patent. Multiple ANDA applicants could launch quickly, creating sharp price erosion.

Scenario 4: At-risk launch

A generic company launches before final resolution of patent litigation. Bristol Myers Squibb could seek damages and injunctive relief, while the generic faces substantial liability exposure.

Scenario 5: Indication-specific competition

A generic obtains approval with carved-out labeling while Sotyktu retains protection for one or more patented uses. This can produce partial rather than immediate erosion.

What is Sotyktu’s geographic coverage?

Bristol Myers Squibb has pursued regulatory approvals and commercialization in major markets outside the United States, including Europe and Japan. Geographic performance depends on local reimbursement, national pricing negotiations, psoriasis treatment guidelines, and the timing of regulatory approvals.

The United States is likely to remain the principal value market because of its higher pharmaceutical pricing and broad specialty-pharmacy infrastructure. Europe offers a large patient base but lower net pricing and longer market-access negotiations. Japan has a distinct reimbursement and prescribing environment and generally contributes less absolute revenue than the United States or major European markets.

How strong is the Sotyktu patent estate?

The Sotyktu patent estate is commercially meaningful because it combines a novel chemical entity with multiple potential layers of protection. The strongest protection is expected to come from compound claims covering deucravacitinib itself. Formulation and process patents can extend defense but are more vulnerable to design-around strategies.

Patent strength depends on:

• Claim breadth.
• Prior-art exposure.
• Written-description and enablement support.
• Patent-term adjustment and extension.
• Orange Book listing status.
• Enforceability against ANDA products.
• The number of independent generic applicants.

The product’s likely exclusivity profile is stronger than that of a drug protected only by method-of-use patents, but the practical duration will depend on litigation and settlement outcomes.

Key Takeaways

• Sotyktu is Bristol Myers Squibb’s selective oral TYK2 inhibitor for moderate-to-severe plaque psoriasis.
• U.S. approval occurred in September 2022.
• Reported sales rose from approximately $25 million in 2022 to approximately $277 million in 2023.
• Growth depends on psoriasis adoption, international commercialization, and expansion into psoriatic arthritis, lupus, and gastrointestinal disease.
• The product competes with IL-17 and IL-23 biologics, Otezla, JAK inhibitors, and other TYK2 programs.
• Sotyktu faces generic, not biosimilar, competition.
• Five-year new-chemical-entity exclusivity generally extends into September 2027.
• Core patent protection is expected to extend into the late 2030s, subject to patent-specific analysis and litigation.
• No major publicly disclosed Paragraph IV settlement or market-moving generic launch had been established in the early launch period.
• The product’s long-term value depends more on label expansion and durable differentiation than on psoriasis alone.

FAQs About Sotyktu Market and Patent Risk

Is Sotyktu a biologic drug?

No. Sotyktu is an orally administered small-molecule drug containing deucravacitinib. Future competitors would generally use the ANDA generic pathway rather than the biosimilar pathway.

Is Sotyktu a JAK inhibitor?

No. Sotyktu is a selective TYK2 inhibitor. It binds the TYK2 regulatory pseudokinase domain and is pharmacologically distinct from conventional JAK1, JAK2, and JAK3 inhibitors.

What company owns Sotyktu?

Bristol Myers Squibb owns and commercializes Sotyktu globally. The product originated within the company’s immunology research and development operations.

Can Sotyktu be used for psoriatic arthritis?

The FDA approval cited here is for moderate-to-severe plaque psoriasis. Use in psoriatic arthritis depends on regulatory approval in the relevant jurisdiction and indication-specific labeling.

What would reduce Sotyktu’s valuation most?

The largest risks are failure of expansion studies, weak payer positioning against IL-23 biologics, unfavorable long-term safety data, and an early generic settlement or successful Paragraph IV challenge.

References

1. Bristol Myers Squibb. (2024). 2023 annual report. https://www.bms.com
2. U.S. Food and Drug Administration. (2022, September 9). FDA approves new treatment for adults with moderate-to-severe plaque psoriasis. https://www.fda.gov
3. Armstrong, A. W., et al. (2023). Deucravacitinib versus placebo and apremilast in moderate-to-severe plaque psoriasis: POETYK PSO-1 and POETYK PSO-2. Journal of the American Academy of Dermatology.
4. United States Patent and Trademark Office. (n.d.). U.S. Patent No. 10,519,175. https://patents.google.com
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov
6. U.S. Food and Drug Administration. (n.d.). Small business assistance: Frequently asked questions on the regulatory exclusivity provisions. https://www.fda.gov
7. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).

DrugChatter Q&A for SOTYKTU

Sotyktu mechanism of action?
Sotyktu for scalp psoriasis?
Sotyktu patent expiry date?
Sotyktu patent expiration?
How much does sotyktu cost?